二尖瓣手术中三尖瓣修复与起搏器植入的相关性:来自心胸外科临床试验网络随机试验的见解
该随机试验纳入401例因退行性二尖瓣反流接受二尖瓣手术的患者,比较单纯二尖瓣手术与同期三尖瓣环成形术。2年内起搏器植入率在三尖瓣环成形组为16.0%,单纯手术组为3.2%(率比5.08,95%CI 2.16-11.94,P<.001)。三尖瓣环成形术、年龄增长和基线左心室射血分数是起搏器植入的独立危险因素。
要点
- 三尖瓣环成形术组2年内起搏器植入率16.0%,单纯二尖瓣手术组3.2%(率比5.08,P<.001)。
- 80.6%(29/36)的起搏器植入发生在术后30天内。
- 独立危险因素包括三尖瓣环成形术(HR 5.94)、年龄增长(每5年HR 1.23)和左心室射血分数(HR 0.96)。
核心结论
- 同期三尖瓣环成形术、年龄和基线左心室射血分数是退行性二尖瓣反流患者二尖瓣手术后起搏器植入的危险因素。
- 三尖瓣环成形术虽能有效预防三尖瓣反流进展,但需要创新方法以降低起搏器植入率。
研究设计与样本
- 随机对照试验,共纳入401例患者,单纯二尖瓣手术组203例,二尖瓣手术+三尖瓣环成形术组198例。
- 采用多变量时间-事件模型评估起搏器植入的潜在危险因素,以死亡和因心力衰竭指征起搏器植入作为竞争风险。
主要发现
- 2年内共有36例(9.6%;95%CI 6.8-13.0)植入起搏器,其中二尖瓣手术+三尖瓣环成形术组30/187(16.0%),单纯二尖瓣手术组6/188(3.2%),率比5.08(95%CI 2.16-11.94;P<.001)。
- 大多数(29/36;80.6%)起搏器植入发生在术后30天内。
- 2年内起搏器植入的独立危险因素:三尖瓣环成形术(HR 5.94;95%CI 2.27-15.53;P<.001)、年龄增长(每5年,HR 1.23;95%CI 1.01-1.52;P=.04)、左心室射血分数(HR 0.96;95%CI 0.92-0.99;P=.02)。
- 在三尖瓣环成形术接受者亚组(n=197)中,年龄(每5年,HR 1.05;95%CI 1.00-1.10;P=.04)和左心室射血分数(HR 0.95;95%CI 0.91-0.99;P=.01)与2年内起搏器植入相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In a recent trial, tricuspid annuloplasty (TA) during mitral valve surgery (MVS) for degenerative mitral regurgitation and moderate or less tricuspid regurgitation (TR) reduced the composite rate of death, reoperation for TR, or TR progression at 2 years. However, this benefit was counterbalanced by an increase in implantation of permanent pacemakers (PPMs). In this study, we analyzed the timing, indications, and risk factors for these implantations. METHODS: We randomized 401 patients (MVS alone = 203; MVS + TA = 198). Potential risk factors for PPMs were assessed using multivariable time-to-event models with death and PPM implantation for heart failure indications as competing risks. RESULTS: A PPM was implanted in 36 patients (9.6; 95% CI, 6.8-13.0) within 2 years of randomization, with 30/187 (16.0%) in the MVS + TA and 6/188 (3.2%) in the MVS groups (rate ratio, 5.08; 95% CI, 2.16-11.94; P < .001). Most (29/36; 80.6%) implantations occurred within 30 days postoperatively. Independent risk factors for PPM implantation within 2 years were TA (hazard ratio [HR], 5.94; 95% CI, 2.27-15.53; P < .001), increasing age (5 years, HR, 1.23; 95% CI, 1.01-1.52; P = .04), and left ventricular ejection fraction (LVEF; HR, 0.96; 95% CI, 0.92-0.99; P = .02). In the subset of TA recipients (n = 197), age (5 years, HR, 1.05; 95% CI, 1.00-1.10; P = .04) and LVEF (HR, 0.95; 95% CI, 0.91-0.99; P = .01) were associated with PPM within 2 years. CONCLUSIONS: Concomitant TA, age, and baseline LVEF were risk factors for PPM implantation in patients who underwent MVS for degenerative mitral regurgitation. Although TA was effective in preventing progression of TR, innovation is needed to identify ways to decrease PPM implantation rates.
引用
- Ailawadi G, Voisine P, Raymond S, et al. Pacemaker implantation associated with tricuspid repair in the setting of mitral valve surgery: Insights from a Cardiothoracic Surgical Trials Network randomized trial. J Thorac Cardiovasc Surg. 2022. PMID: 36669972. doi:10.1016/j.jtcvs.2022.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。